A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke
Stroke, Acute, Neurological Impairment
About this trial
This is an interventional treatment trial for Stroke, Acute
Eligibility Criteria
Inclusion Criteria: Patient having had a single infarct in the carotid artery territory 3 to 8 days before inclusion Patient with a moderately severe or severe disability (Modified Rankin Score 4 or 5) Patient having a Quick's Test (for INR) and APPT (activated partial prothrombin time) test in the normal values of the laboratory Exclusion Criteria: Patients having had an ischemic stroke (CT confirmed) less than 3 days and more than 8 days prior Patient with known pre-existent cerebral infarction Infarct damaged area bigger than 1/3 hemisphere Patient having a score below the cut-off point at Frenchay Aphasia Short Test
Sites / Locations
- Faculty of Medicine in Hradec Kralove
- General Faculty Hospital
- Department and Clinic of Neurology of the Old Age
- CMUJ Krakov
- Postgraduate Medical Teaching Center
- Institul de Boli Cerebro Vascular
- Spitalul Universitar de Urgenta
- Russian State Medical University - Neurology and Neurosurgery Clinic
- Russian State Medical University - Dept Fundamental Neurology & Neurosurgery
- Ural State Medical Academy
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
EGb761®
Placebo
EGb761® 240 milligrams (mg)/day for 6 months administered orally, in association with acetylsalicylic acid (325 mg/day). The test treatment consists of 6 tablets/day. 2 tablets (each containing 40 mg EGb761®) taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch.
6 months, administered orally, in association with acetylsalicylic acid (325 mg/day). The placebo consists of 6 tablets/day. 2 tablets taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch.